In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with ...

Two small clinical trials tested the safety of injecting stem cells into the brains of Parkinson's patients and found no ...

Autologous mononuclear cells showed substantial activity in patients with advanced heart failure — and even though the study ...

The following is a summary of "A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study," ...

The "Graft Versus Host Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The Global ...

Two new studies suggest that Parkinson's disease can potentially be treated with stem cells placed in a patient's brain.

Exicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myeloma: Redwood City, California Wednesday, April 16, 2025, 18:00 Hrs [IS ...

Induced pluripotent stem cells are being tested to treat blindness, paralysis, Parkinson’s disease and more. Approvals might ...

Explore the advancements in stem cell therapy for neurodegenerative diseases. Discover market size, trends, and growth projections for 2035 with a focus on treatment innovations.

Johnson & Johnson (J&J) has received approval from the European Commission (EC) for its subcutaneous (SC) Darzalex (daratumumab)-based quadruplet regimen in newly diagnosed multiple myeloma (MM).

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...